Lemaitre Vascular (LMAT) Net Income towards Common Stockholders (2010 - 2026)

Lemaitre Vascular (LMAT) has 17 years of Net Income towards Common Stockholders data on file, last reported at $15.7 million in Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at $15.7 million, up 42.39% year-over-year; the trailing twelve-month figure through Mar 2026 was -$10.3 million (down 123.07% YoY), and the FY2025 annual result was -$15.0 million, down 134.38% from the prior year.
• Net Income towards Common Stockholders improved to $15.7 million in Q1 2026 per LMAT's latest filing, from -$57.1 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $17.4 million in Q3 2025 and troughed at -$57.1 million in Q4 2025.
• A 5-year average of $5.5 million and a median of $8.1 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders soared 130.38% in 2023, then plunged 632.34% in 2025.
• A 5-year view of Net Income towards Common Stockholders shows it stood at $5.4 million in 2022, then surged by 30.93% to $7.1 million in 2023, then surged by 50.55% to $10.7 million in 2024, then sank by 632.34% to -$57.1 million in 2025, then jumped by 127.44% to $15.7 million in 2026.
• Business Quant data shows LMAT's Net Income towards Common Stockholders at $15.7 million in Q1 2026, -$57.1 million in Q4 2025, and $17.4 million in Q3 2025.